Latest Headlines

Latest Headlines

AMRI piles on profits with strong Q1

AMRI's days of posting quarterly net losses appear to be far behind, as the company rode an 11% revenue jump to $6.5 million in net income, up from a negative $3.8 million in the same period last year.

Sanofi sees Shantha Biotech's Shan5 back in 2014

When Sanofi bought an 80% stake in Indian vaccinemaker Shantha Biotech in 2009, the talk was of the deal accelerating growth in emerging markets.Things played out a little differently though.

AMRI inks 5-year CDMO deal with Ono

AMRI has locked down another 5-year partnership with Japan's Ono Pharmaceutical, agreeing to provide development and manufacturing services for the company's treatments, which include a promising multiple sclerosis drug.

Catalent quadruples biologics capacity with new plant

Citing a boom in demand for biologics, Catalent has cut the ribbon on a new biomanufacturing facility in Madison, WI, a plant the company says will quadruple its capacity.

Novartis expands cell culture site to bolster biodefense

The spread of H7N9 in China is a reminder of why the Department of Health and Human Services (HHS) gave Novartis $487 million to build its cell culture vaccine production plant. If H7N9 reaches the U.S., the country will be better prepared because of the investment.

GSK, Allergan marred by CMO setbacks

Two big-time drugmakers are having to put their plans on hold thanks to problems with contract manufacturers, with GlaxoSmithKline facing a prolonged drug shortage and Allergan enduring an FDA rejection.

Indian CMO Shasun inks Alzheimer's deal with Debiopharm

Swiss drugmaker Debiopharma has teamed up with India's Shasun Pharmaceuticals, striking a deal with the CMO to manufacture Huperzine-A, a drug designed to improve cognitive performance in patients with Alzheimer's disease.

Catalent jumps into ADCs with Redwood deal

As more and more drugmakers eye antibody-drug conjugate development as a path to blockbusters, Catalent has licensed ADC technology from Redwood Bioscience, planning to roll the offering into its service platform.

Frontage gets FDA chiding over Chinese lab

U.S. CRO Frontage has received a Form 483 from the FDA after an inspection of its bioanalytical lab in Shanghai.

Sanofi beefs up CMO game with Transgene deal

France's Sanofi is expanding its contract manufacturing capabilities, teaming up with Transgene to spend $13 million on a new CMO platform.